Advaxis Appoints Anthony Lombardo as Chief Business Officer
April 19 2017 - 8:00AM
Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company
developing cancer immunotherapies, today announced that Anthony A.
Lombardo, an industry veteran with nearly 30 years’ experience in
the field of life sciences, has joined the company as Chief
Business Officer. Lombardo is a senior leader with extensive
experience in helping global companies achieve significant growth.
Previously, Lombardo was President and CEO of
E-Z-EM Inc., a company focusing on oral imaging contrast
agents. As E-Z-EM CEO, he created shareholder value through a
spinout of AngioDynamics, Inc., the development of new products,
and the subsequent sale of E-Z-EM. His actions transformed
the company in eight years to a combined value of approximately
$450 million, up from a market value of approximately $10 million
at the time that he joined the company. Under his leadership,
E-Z-EM was placed on Forbes’ list of the Best Small Companies in
America in 2007.
“Tony has led successful companies, achieved
aggressive milestones and driven growth at all levels,” said Daniel
J. O’Connor, President and Chief Executive Officer of Advaxis. “His
leadership, knowledge and experience will be assets to
Advaxis.”
Lombardo joined Advaxis from The Channel Group,
where he was a Partner providing strategic advisory services to
biotechnology, pharma and med-tech companies. Previously, he
was Chief Operating Officer of Bracco Diagnostics, overseeing
business operations for six years. Prior to joining E-Z-EM,
the company Bracco acquired, Lombardo served as the President of
ALI Imaging Systems, Inc., the U.S. subsidiary of ALI Technologies,
where he led all U.S. based assets and was responsible for
strategic planning and B2B relationships. That company was sold to
McKesson for $340 million. He has also held leadership roles at
General Electric Medical Systems, Philips Medical Systems,
Loral/Lockheed Martin Corp. and Sony Corporation.
Lombardo recently was honored by the American
College of Radiology and the Society of Abdominal Radiology for his
years of service to the clinical community. He serves as
Chairman of the Advisory Board of Morristown Medical Center, a part
of Atlantic Health System Hospitals. He received an M.S. in
Physiology from Duquesne University and a B.S. in Biology from St.
Francis College.
Lombardo’s appointment was effective April
17. As part of his compensation, he received 100,000
restricted stock units in Advaxis, of which 25 percent vest
immediately and the remaining shares vest annually over the next
three years.
About Advaxis, Inc.
Located in Princeton, N.J., Advaxis, Inc. is a
biotechnology company developing multiple cancer immunotherapies
based on its proprietary Lm Technology™.
The Lm Technology, using bioengineered live
attenuated Listeria monocytogenes (Lm) bacteria, is the
only known cancer immunotherapy agent shown in preclinical studies
to both generate cancer fighting T cells directed against cancer
antigens and neutralize Tregs and myeloid-derived suppressor cells
(MDSCs) that protect the tumor microenvironment from immunologic
attack and contribute to tumor growth. Advaxis'
lead Lm Technology immunotherapy, axalimogene filolisbac,
targets HPV-associated cancers and is in clinical trials for three
potential indications: Phase 3 in invasive cervical cancer, Phase 2
in metastatic cervical cancer, Phase 2 in head and neck cancer, and
Phase 2 in anal cancer. The FDA has granted axalimogene filolisbac
orphan drug designation for each of these three clinical settings,
as well as Fast Track designation for adjuvant therapy for HRLACC
patients and a SPA for the Phase 3 AIM2CERV trial in HRLACC
patients. Axalimogene filolisbac has also been classified as an
advanced therapy medicinal product for the treatment of cervical
cancer by the EMA’s CAT. Advaxis has two additional immunotherapy
products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2
expressing solid tumors, in human clinical development. In
addition, Advaxis and Amgen are developing ADXS-NEO, an
investigational cancer immunotherapy treatment designed to activate
a patient's immune system to respond against the unique mutations,
or neoepitopes, contained in and identified from each individual
patient's tumor, with plans to commence a Phase 1 clinical trial in
2017.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook, and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements, including, but not limited to, statements regarding
Advaxis’ ability to develop the next generation of cancer
immunotherapies, and the safety and efficacy of Advaxis’
proprietary immunotherapy, axalimogene filolisbac. These
forward-looking statements are subject to a number of risks
including the risk factors set forth from time to time in Advaxis’
SEC filings including, but not limited to, its report on Form 10-K
for the fiscal year ended October 31, 2016, which is available at
http://www.sec.gov.
Any forward-looking statements set forth in this
presentation speak only as of the date of this presentation. We do
not intend to update any of these forward-looking statements to
reflect events or circumstances that occur after the date hereof
other than as required by law.
You are cautioned not to place undue reliance on
any forward-looking statements.
CONTACTS:
Company:
Advaxis, Inc. Noelle Heber heber@advaxis.com 609.250.7575
Media Contact:
JPA Health Communications David Connolly dconnolly@jpa.com
617.657.1301
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Sep 2023 to Sep 2024